Trial · NCT02409342
Results by group741
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 741
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 13.1 | 95% Confidence Interval 7.4 to 16.5 | Months | |
| Overall Survival (OS) in the TC3 or IC3-WT Populations | Atezolizumab | 20.2 | 95% Confidence Interval 16.5 to NA | Months | |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC2/3 or IC2/3-WT Population | 16.1 | 95% Confidence Interval 12.6 to 18.0 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC2/3 or IC2/3-WT Population | 19.9 | 95% Confidence Interval 17.2 to 25.3 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC1/2/3 or IC1/2/3-WT Population | 14.7 | 95% Confidence Interval 11.2 to 16.5 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC1/2/3 or IC1/2/3-WT Population | 18.9 | 95% Confidence Interval 13.4 to 23.0 | Months |
| Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 5.0 | 95% Confidence Interval 4.2 to 5.7 | Months | |
| Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | Atezolizumab | 8.1 | 95% Confidence Interval 6.8 to 11.0 | Months | |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC2/3 or IC2/3-WT Population | 5.5 | 95% Confidence Interval 4.5 to 5.7 | Months |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC2/3 or IC2/3-WT Population | 7.3 | 95% Confidence Interval 5.6 to 9.3 | Months |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC1/2/3 or IC1/2/3-WT Population | 5.6 | 95% Confidence Interval 4.7 to 5.7 | Months |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC1/2/3 or IC1/2/3-WT Population | 5.8 | 95% Confidence Interval 5.5 to 7.3 | Months |
| Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 28.6 | Percentage of participants | ||
| Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | Atezolizumab | 38.3 | Percentage of participants | ||
| Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC2/3 or IC2/3-WT Population | 32.1 | Percentage of participants | |
| Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC2/3 or IC2/3-WT Population | 33.7 | Percentage of participants | |
| Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC1/2/3 or IC1/2/3-WT Population | 32.1 | Percentage of participants | |
| Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC1/2/3 or IC1/2/3-WT Population | 31.4 | Percentage of participants | |
| Duration of Response (DOR) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 6.7 | 95% Confidence Interval 5.5 to 17.3 | Months | |
| Duration of Response (DOR) in the TC3 or IC3-WT Populations | Atezolizumab | NA | 95% Confidence Interval 11.8 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02409342/results